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Abstract
Background—Although pneumonia has been suggested as a risk factor for lung cancer, previous
studies have not evaluated the influence of number of pneumonia diagnoses in relation to lung cancer
risk.
Methods—The Environment And Genetics in Lung cancer Etiology (EAGLE) population-based
study of 2,100 cases and 2,120 controls collected information on pneumonia more than one year
before enrollment from 1,890 cases and 2,078 controls.
Results—After adjusting for study design variables, smoking, and chronic bronchitis, pneumonia
was associated with decreased risk of lung cancer (odds ratio (OR), 0.79; 95% confidence interval
(CI), 0.64–0.97), especially among individuals with ≥3 diagnoses versus none (OR, 0.35; 95% CI,
0.16–0.75). Adjustment for chronic bronchitis contributed to this inverse association. In comparison,
pulmonary tuberculosis was not associated with lung cancer (OR, 0.96; 95% CI, 0.62–1.48).
Conclusions—The apparent protective effect of pneumonia among individuals with multiple
pneumonia diagnoses may reflect an underlying difference in immune response and requires further
investigation and confirmation.
Impact—Careful evaluation of number of pneumonia episodes may shed light on lung cancer
etiology.
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Introduction
Pulmonary infections have been proposed as risk factors for lung cancer (1). Respiratory tract
infections may contribute to lung carcinogenesis by promoting airway remodeling (2) and
causing inflammation, which can generate reactive oxygen or nitrogen species, increase
cellular proliferation, upregulate antiapoptotic pathways, and stimulate angiogenesis (1). Both
self-reported pneumonia and Chlamydia pneumoniae have been associated with increased lung
cancer risk (1,3). While previous studies have evaluated any diagnosis of pneumonia and lung
cancer, to our knowledge no previous study has analyzed the number of pneumonia diagnoses.
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The Environment And Genetics in Lung cancer Etiology population-based case control study
(EAGLE) collected information on the number of self-reported pneumonia diagnoses, allowing
detailed evaluation of the association with pneumonia. We also analyzed tuberculosis (TB).
Materials and Methods
As previously described (4), EAGLE enrolled 2,100 consecutive incident lung cancer cases
from 13 hospitals in the Lombardy region of northern Italy, which accounted for approximately
80% of all lung cancer cases in the municipalities selected for the study, and 2,120 population-
based controls randomly sampled from the Regional Health Service database and frequency
matched to cases by age, sex, and area of residence. Of all eligible subjects, 86.6% of cases
and 72.4% of controls agreed to participate and provided informed consent approved by the
Institutional Review Boards of each participating hospital and university in Italy and the
National Cancer Institute. All enrolled subjects were Caucasian.
Information on history of pneumonia and TB, including ages at diagnoses, was collected from
cases and controls using a computer-assisted personal interview (CAPI). Data were collected
for age at first, second, and third diagnosis of pneumonia, allowing evaluation of latency as
the difference between study age (age at first diagnosis of lung cancer for cases or age at
interview for controls) and age at first diagnosis. Seven cases and seven controls whose date
of first pneumonia diagnosis was less than one year before study entry were excluded, leaving
2,094 cases and 2,113 controls. Of these, 1,890 (90.3%) cases and 2,078 (98.3%) controls
provided data on pneumonia. These percentages are similar to the overall CAPI completion
rates (cases, 92.6%; controls, 99.8%).
Lung cancer was confirmed from surgery, biopsy, or cytology samples in approximately 95%
of cases, with confirmation through clinical history and imaging for the remainder (4). Main
analyses included all primary lung cancer cases regardless of histological type, while histology-
specific analyses included only adenocarcinoma, squamous cell carcinoma, large cell
carcinoma, and small cell carcinoma, as defined by the WHO Histological Typing of Lung and
Pleural Tumors (1999).
Odds ratios (ORs) and 95% confidence intervals (CIs) for associations with lung cancer were
calculated through unconditional binary logistic regression for main analyses and polytomous
logistic regression for analyses by histological type. All models included the design variables
(study age, gender, and region) on which controls were frequency matched to cases. After
backwards modeling to evaluate smoking (e.g., smoking intensity (average packs per day),
time between last smoking quit attempt and study entry), demographic/socioeconomic
variables (e.g., education, marital status), chronic bronchitis, emphysema, asthma, TB, family
history of lung cancer in first degree relatives, and other factors as potential confounders, only
the removal of chronic bronchitis changed the beta coefficient for pneumonia by more than
10%. However, in accord with several recent studies of adjustment for smoking (5–7),
continuous pack-years and smoking intensity were included with history of chronic bronchitis
in the final models. Additional smoking variables (time since quitting smoking, age at initiation
of cigarette smoking, environmental tobacco smoke in childhood or adulthood (at work or
home), and other tobacco smoking) had little impact on the ORs for pneumonia or TB and were
not included in the final models. Similarly, additional adjustment for other self-reported
previous lung diseases (emphysema, asthma, and TB in the pneumonia models) did not
substantively change the results.
Effect modification by smoking and latency was evaluated using likelihood ratio tests (LRTs)
for interaction. Differences in ORs for separate histological types were evaluated with the Wald
test for homogeneity.
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Results
The distribution of cases and controls is described in Table 1. Sixteen percent of cases
(296/1,890) and 15% of controls (318/2,078) reported one or more pneumonia diagnoses (χ2
P = 0.8). Three percent of both cases (61/1,881) and controls (62/2,070) reported TB (P = 0.3).
The mean age at first diagnosis among cases and controls was 32.6 (median, 29; range, 0–78)
for pneumonia and 24.9 (median, 22; range, 2–73) for TB. Over 90% of TB diagnoses were
reported as occurring more than 20 years prior to study enrollment, compared to approximately
65% of initial pneumonia diagnoses. Pneumonia and TB were not associated: <1% of cases
(n = 16) or controls (n = 17) had both.
The median time between diagnoses was 10 years (range, 1–71) among 87 people who reported
age at first and second pneumonia diagnoses and 3 years (range, 1–33) among 23 people who
reported age at second and third pneumonia diagnoses, suggesting separate episodes rather
than unresolved infection. The median time between diagnoses was similar for cases and
controls.
After adjustment, pneumonia reduced the risk of lung cancer (Table 2). This association did
not vary by smoking status (LRT P = 0.6). The protective effect was strongest for patients with
≥3 diagnoses versus patients with no pneumonia diagnoses (OR, 0.35; 95% CI, 0.16–0.75).
This pattern was similar for never, former, and current smokers, and the OR for pneumonia
overall was similar if additionally adjusted for smoking status (OR: 0.78, 95% CI: 0.63– 0.96).
Among subjects reporting pneumonia, the OR for ≥3 versus 1–2 diagnoses was 0.44 (95% CI,
0.20–0.97). Removal of chronic bronchitis from the model raised the fully adjusted OR for
pneumonia from 0.79 (95% CI, 0.64–0.97) to 0.88 (95% CI, 0.72–1.08). While removing pack-
years and smoking intensity had little effect (OR, 0.81; 95% CI, 0.67–0.98), removal of chronic
bronchitis in addition to the smoking variables brought the OR to 0.99 (0.83–1.18). In contrast
to pneumonia, TB was not associated with lung cancer (Table 2). Although risk of lung cancer
increased somewhat across smoking status (LRT P = 0.02), numbers were quite small.
We evaluated the joint effects of pneumonia and chronic bronchitis (Table 3). The OR for
pneumonia and lung cancer in individuals without chronic bronchitis was 0.83 (0.65–1.05),
while chronic bronchitis was associated with increased risk of lung cancer regardless of
pneumonia status. Even among individuals with chronic bronchitis, however, pneumonia had
a protective effect (1.6/2.5=0.66; 95% CI, 0.43–1.04).
Pneumonia was not associated with attempting to quit smoking (OR, 1.05; 95% CI, 0.83–1.33)
or number of quit attempts (P-trend = 1.0). The number of pneumonia diagnoses was similarly
not associated with quitting smoking (data not shown). Among cases, neither pneumonia nor
number of pneumonia diagnoses was associated with tumor stage (data not shown).
In addition to tumor stage, the associations for pneumonia and for TB did not vary by histology
(Wald P = 0.8 and 0.7, respectively), although numbers were small for some histology
categories. Histological results were similar when stratified by smoking status (data not
shown). Likewise, associations of pneumonia and TB with lung cancer did not vary by quartiles
of latency (LRT P = 0.7). ORs were inverse for individuals with ≥3 pneumonia diagnoses with
no clear pattern by latency, while individuals with 1 or 2 diagnoses had inconsistent patterns
tending to cluster around 1.0 (Table 4). Results were similar using latency calculated with the
last known pneumonia diagnosis instead of the first.
Discussion
To our knowledge, this study is the first to evaluate the number of reported pneumonia
diagnoses and lung cancer. Previous pneumonia was associated with decreased risk of lung
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cancer, especially among individuals reporting ≥3 pneumonia diagnoses, whereas previous TB
exhibited no association. Additional adjustment for smoking beyond pack-years and smoking
intensity did not materially change these results, and there were no clear patterns by latency.
While previous studies generally have found positive associations between self-reported
pneumonia and lung cancer (8–17), only one (15) controlled for chronic bronchitis. Since
chronic bronchitis is clearly associated with increased risk of lung cancer (18) regardless of
pneumonia status, chronic bronchitis may mask the true effect of pneumonia if chronic
bronchitis is not taken into account. The etiologic factors for chronic bronchitis include
smoking, genetics, and occupational and environmental exposures (19). Pneumonia is not
thought to be important in etiology since studies such as Framingham establish that infectious
exacerbations do not influence the underlying progression in decline of FEV1 (forced
expiratory volume in 1 second) characteristic of chronic obstructive pulmonary disease (19).
Since this evidence suggests that chronic bronchitis is not a key intermediate on the pathway
from pneumonia to lung cancer, adjustment for chronic bronchitis was considered appropriate.
Although longitudinal data are needed to clarify the relation between chronic bronchitis and
pneumonia further, pneumonia reduced lung cancer risk even among subjects reporting no
chronic bronchitis (OR, 0.83; 95% CI: 0.65–1.05). Adjusting for other lung diseases associated
with lung cancer (18), such as emphysema, did not affect the association between pneumonia
and lung cancer.
In our study, the inverse association appeared to be driven largely by the number of pneumonia
diagnoses, although it is important to note that few individuals had ≥3 diagnoses. Previous
studies have not addressed this issue. It is possible that having multiple bouts of pneumonia
reflects some difference in immune function resulting in repeated pneumonia and an attenuated
inflammatory response leading to slower progression to malignancy. Such an effect could be
genetically mediated since family history of pneumonia also appears to decrease the risk of
lung cancer, especially among older individuals (20). Alternatively, antibiotic treatment for
pneumonia may eliminate infectious agents reported to increase lung cancer risk, such as
Chlamydia pneumoniae (3). Thus, repeated treatment courses for multiple bouts of pneumonia
might decrease the risk of lung cancer. Although people with pneumonia might, in theory, be
more likely to reduce or quit smoking or avoid other environmental risk factors for lung cancer,
adjusting for smoking and other factors only strengthened the inverse association in our study.
Finally, the “immunesurveillance hypothesis” proposed for asthma may be relevant in this
case: multiple bouts of pneumonia may stimulate the immune system such that it is better able
to detect and destroy cancer cells (21). While we are unsure why we see inverse associations,
our findings warrant further investigation in other studies with data on multiple pneumonia
diagnoses.
TB and lung cancer exhibited no association in our data. Reported associations between TB
and lung cancer have been inconsistent (8–12,15–17,22–25) and often weaker with longer
latency (9,16,22,25). In our study, the median age at TB diagnosis was 22, and diagnosis
occurred more than 20 years prior to interview in over 90% of subjects. Thus, it may not be
surprising that we found no association since the association between TB and lung cancer
weakens with longer latency (22). Individuals diagnosed with TB at a young age may tend to
avoid risk factors like smoking, thus reducing their risk for lung cancer.
These results must be interpreted with caution given the potential for misclassification through
self-report and the small number of subjects with ≥3 pneumonia diagnoses. Although recall
bias is of concern as in all case-control studies, the same persons did not report both pneumonia
and TB, suggesting that there was not consistent differential error in reporting incases or
controls. While it is theoretically possible that lung cancer may be diagnosed earlier in exposed
individuals due to increased medical investigations like chest X-rays, pneumonia was not
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associated with tumor stage. In addition, such surveillance bias would increase the OR and
thus cannot account for the inverse association we observed between pneumonia and lung
cancer, but could lead to a bias towards a weaker estimate of effect.
EAGLE is an excellent setting in which to evaluate pneumonia and lung cancer given its large
size, population-based design, detailed questionnaires including number of pneumonia
diagnoses, and high participation rate. Interviewers were centrally trained to ensure accurate
and complete data collection. Data collection and transfer were further protected through
extensive quality control procedures (4).
In one of the largest studies of previous pneumonia and lung cancer to date and the first to our
knowledge to report on number of pneumonia diagnoses, we found a novel inverse association
between pneumonia and lung cancer. Given that this result was largely limited to people with
≥3 pneumonia diagnoses, we speculate that some immune perturbation or effect of treatment
accounts for the decreased risk of lung cancer in these individuals. Future studies focused on
these individuals, perhaps with specific attention to genetic polymorphisms, may help elucidate
the underlying mechanisms involved in lung carcinogenesis.
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Table 1
Descriptive characteristics of cases and controls providing data on pneumonia at least one year prior to entry into
the Environment And Genetics in Lung cancer Etiology (EAGLE) case-control study.
Characteristic Cases (N = 1890) Controls (N = 2078) P-value
Median age (range) 67 (35–80) 66 (35–80) 0.02
% male 79.2 76.4 0.04
Study area N (%) 0.9
 Brescia 238 (12.6) 242 (11.6)
 Milano 1242 (65.7) 1417 (68.2)
 Monza 129 (6.8) 116 (5.6)
 Pavia 125 (6.6) 126 (6.1)
 Varese 156 (8.3) 177 (8.5)
% ever smokers 93.0 67.8 <0.0001
 Median smoking intensity (average packs/day) 1.0 0.75 <0.0001
 Median duration of smoking (years) 44 33 <0.0001
Education, N (%)* <0.0001
 None 107 (5.7) 90 (4.3)
 Elementary 734 (38.9) 557 (26.8)
 Middle school 541 (28.6) 601 (28.9)
 High school 411 (21.8) 568 (27.3)
 University 96 (5.1) 262 (12.6)
% Married/cohabitating 77.0 82.8 <0.0001
*
Does not sum to total due to missing values
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2011 March 3.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Koshiol et al. Page 8
Ta
bl
e 
2
O
dd
s r
at
io
s (
O
R
) a
nd
 9
5%
 c
on
fid
en
ce
 in
te
rv
al
s (
C
I)
 fo
r a
ss
oc
ia
tio
ns
 o
f l
un
g 
ca
nc
er
 w
ith
 p
ne
um
on
ia
 a
nd
 tu
be
rc
ul
os
is
 d
ia
gn
os
ed
 a
t l
ea
st
 o
ne
 y
ea
r p
rio
r t
o 
en
try
 in
to
 th
e 
En
vi
ro
nm
en
t A
nd
 G
en
et
ic
s i
n 
Lu
ng
 c
an
ce
r
Et
io
lo
gy
 (E
A
G
LE
) c
as
e-
co
nt
ro
l s
tu
dy
, b
ot
h 
ov
er
al
l a
nd
 st
ra
tif
ie
d 
by
 sm
ok
in
g 
st
at
us
.
Sm
ok
in
g 
St
at
us
O
ve
ra
ll
N
ev
er
Fo
rm
er
C
ur
re
nt
C
as
es
n=
18
46
 (%
)
C
on
tr
ol
s
n=
20
54
 (%
)
O
R
 (9
5%
 C
I)
*
C
as
es
n=
13
1 
(%
)
C
on
tr
ol
s
n=
66
6 
(%
)
O
R
 (9
5%
 C
I)
*
C
as
es
n=
79
1 
(%
)
C
on
tr
ol
s
n=
87
9 
(%
)
O
R
 (9
5%
 C
I)
*
C
as
es
n=
92
4 
(%
)
C
on
tr
ol
s
n=
50
9 
(%
)
O
R
 (9
5%
 C
I)
*
Pn
eu
m
on
ia
†
 
N
o
15
55
 (8
4.
2)
17
46
 (8
5.
0)
1
11
8 
(9
0.
1)
58
6 
(8
8.
0)
1
64
7 
(8
1.
8)
72
7 
(8
2.
7)
1
79
0 
(8
5.
5)
43
3 
(8
5.
1)
1
 
Y
es
29
1 
(1
5.
8)
30
8 
(1
5.
0)
0.
79
 (0
.6
4–
0.
97
)
13
 (9
.9
)
80
 (1
2.
0)
0.
72
 (0
.3
7–
1.
41
)
14
4 
(1
8.
2)
15
2 
(1
7.
3)
0.
83
 (0
.6
2–
1.
12
)
13
4 
(1
4.
5)
76
 (1
4.
9)
0.
75
 (0
.5
4–
1.
06
)
 
 
1 
di
ag
no
si
s
24
0 
(1
3.
0)
25
3 
(1
2.
3)
0.
81
 (0
.6
5–
1.
02
)
11
 (8
.4
)
61
 (9
.2
)
0.
89
 (0
.4
4–
1.
83
)
11
3 
(1
4.
3)
12
8 
(1
4.
6)
0.
83
 (0
.6
0–
1.
12
)
11
6 
(1
2.
6)
64
 (1
2.
6)
0.
78
 (0
.5
4–
1.
12
)
 
 
2 
di
ag
no
se
s
35
 (1
.9
)
33
 (1
.6
)
0.
97
 (0
.5
5–
1.
71
)
2 
(1
.5
)
12
 (1
.8
)
0.
59
 (0
.1
2–
2.
95
)
22
 (2
.8
)
14
 (1
.6
)
1.
25
 (0
.5
8–
2.
71
)
11
 (1
.2
)
7 
(1
.4
)
0.
78
 (0
.2
8–
2.
20
)
 
 
≥3
 d
ia
gn
os
es
16
 (0
.9
)
22
 (1
.1
)
0.
35
 (0
.1
6–
0.
75
)
0 
(0
.0
)
7 
(1
.1
)
0
9 
(1
.1
)
10
 (1
.1
)
0.
49
 (0
.1
7–
1.
42
)
7 
(0
.8
)
5 
(1
.0
)
0.
38
 (0
.2
2–
1.
30
)
 
P 
-tr
en
d
0.
00
8
0.
1
0.
2
0.
06
Tu
be
rc
ul
os
is
†
 
N
o
17
77
 (9
6.
7)
19
85
 (9
7.
0)
1
12
8 
(9
8.
5)
64
3 
(9
6.
8)
1
76
4 
(9
6.
8)
84
3 
(9
6.
2)
1
88
5 
(9
6.
4)
49
9 
(9
8.
6)
1
 
Y
es
60
 (3
.3
)
61
 (3
.0
)
0.
96
 (0
.6
2–
1.
48
)
2 
(1
.5
)
21
 (3
.2
)
0.
40
 (0
.0
9–
1.
89
)
25
 (3
.2
)
33
 (3
.8
)
0.
87
 (0
.4
8–
1.
58
)
33
 (3
.6
)
7 
(1
.4
)
1.
73
 (0
.7
2–
4.
14
)
* A
dj
us
te
d 
fo
r s
tu
dy
 a
ge
, s
ex
, r
eg
io
n,
 a
nd
 c
hr
on
ic
 b
ro
nc
hi
tis
 fo
r n
ev
er
 sm
ok
er
s a
nd
 a
ls
o 
pa
ck
-y
ea
rs
 a
nd
 sm
ok
in
g 
in
te
ns
ity
 (a
ve
ra
ge
 p
ac
ks
 p
er
 d
ay
) f
or
 sm
ok
er
s a
nd
 o
ve
ra
ll
† O
ve
ra
ll 
nu
m
be
r d
oe
s n
ot
 su
m
 to
 to
ta
l d
ue
 to
 su
bj
ec
ts
 m
is
si
ng
 d
at
a 
on
 o
th
er
 v
ar
ia
bl
es
 in
cl
ud
ed
 in
 th
e 
m
ul
tiv
ar
ia
te
 m
od
el
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2011 March 3.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Koshiol et al. Page 9
Table 3
Distribution of pneumonia among individuals with and without history of chronic bronchitis in the Environment
And Genetics in Lung cancer Etiology (EAGLE) case-control study and odds ratios (OR) and 95% confidence
intervals (CI) for the risk of lung cancer among individuals with pneumonia only, chronic bronchitis only, or
both pneumonia and chronic bronchitis compared to individuals without chronic bronchitis (referent)
History of chronic bronchitis
History of pneumonia* No Yes
No
 n cases 1266 289
 n controls 1659 87
 OR (95% CI)† Referent 2.45 (1.85–3.25)
Yes
 n cases 172 119
 n controls 253 55
 OR (95% CI)† 0.83 (0.65–1.05) 1.63 (1.12–2.36)
*
Numbers do not sum to total due to subjects missing data on other variables included in the multivariate model
†
OR = odds ratio, CI = confidence interval. Adjusted for study age, gender, region, pack-years, and smoking intensity (average packs per day)
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